Ionis: FDA Approves Rare-Disease Drug Dawnzera; Positive Long-Term Outlook and Shares Undervalued

Ionis received approval from the US Food and Drug Administration for Dawnzera (pipeline candidate donidalorsen), marking the first and only RNA-targeted prophylactic treatment for hereditary angioedema, or HAE.